Enanta Pharmaceuticals Inc. raised $20 million in new financing to help carry its lead candidate, EP-013420, a first-in-class bridged bicyclic ketolide antibiotic for community respiratory tract infections, through Phase I development. (BioWorld Today)
Enanta Pharmaceuticals Inc. raised $20 million in new financing to help carry its lead candidate, EP-013420, a first-in-class bridged bicyclic ketolide antibiotic for community respiratory tract infections, through Phase I development. (BioWorld Today)
ROCKVILLE, Md. - An FDA advisory panel Friday leaned toward favoring Macugen, a proposed treatment for age-related macular degeneration expected to have an impact on the aging Baby Boomer population. (BioWorld Today)
ROCKVILLE, Md. - An FDA advisory panel Friday leaned toward favoring Macugen, a proposed treatment for age-related macular degeneration expected to have an impact on the aging Baby Boomer population. (BioWorld Today)
Eyetech Pharmaceuticals Inc. and partner Pfizer Inc. today are scheduled to present data supporting use of the potential blockbuster Macugen as a treatment for neovascular or wet age-related macular degeneration. (BioWorld Today)
Eyetech Pharmaceuticals Inc. and partner Pfizer Inc. today are scheduled to present data supporting use of the potential blockbuster Macugen as a treatment for neovascular or wet age-related macular degeneration. (BioWorld Today)
After achieving statistically significant efficacy endpoints in a second Phase III study, Avanir Pharmaceuticals Inc. said it anticipates seeking regulatory approval later this year for Neurodex in the treatment of pseudobulbar affect, a syndrome that occurs with a number of neurodegenerative diseases. (BioWorld Today)
